In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Merck & Co. Inc.

Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry

In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.

Coronavirus COVID-19 Companies

Stockwatch: The First Coronavirus Earnings Season May Come Early

The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.

Sales & Earnings Stockwatch

Interview: iTeos Attracts Investors By Targeting TIGIT

The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.

Financing ImmunoOncology

Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start

Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.

Coronavirus COVID-19 Infectious Diseases
See All

Company Information

UsernamePublicRestriction

Register